Compare HP Inc (HPQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Regeneron Pharmaceuticals Inc — how do they compare? HP Inc trades at $32.6 (market cap $29.07B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.6× HP Inc's market cap, and HP Inc pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HPQ | REGN | |
|---|---|---|
Market Cap | $29.07B | $76.14B |
Volume | 12,708,293 | 500,239 |
Sector | Technology | Health |
52-Week High | $35.48 | $852.03 |
52-Week Low | $18.20 | $557.73 |
Typical Hold Time | 70 Days | 107 Days |
Enterprise Value | $35.24B | $70.85B |
Dividend Yield | 3.72% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.24, up 1.61% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue for 2025 was $55.3B with a net income margin of 4.14%, though margins have trended down from 6.07% in 2023. The stock offers a dividend yield of 3.82% and trades below analyst consensus price targets, with a P/E of 12.31 suggesting reasonable valuation. News highlights new product launches but also concerns over 2027 PC market declines.
The outlook is mixed: strong cash flow and consistent dividend payments support income investors, but declining PC volumes pose a growth challenge. Analyst consensus is cautious with 54% hold ratings. Key risks include execution in a shrinking market and competitive pressures. The stock presents value characteristics but requires monitoring of top-line stability.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
